Livforsakringsbolaget Skandia Omsesidigt Invests $19.70 Million in United Therapeutics Corporation $UTHR

Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 36,400 shares of the biotechnology company's stock, valued at approximately $19,702,000. Livforsakringsbolaget Skandia Omsesidigt owned approximately 0.08% of United Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Arjuna Capital lifted its position in shares of United Therapeutics by 2.8% during the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock worth $393,000 after acquiring an additional 18 shares in the last quarter. Sage Rhino Capital LLC raised its stake in shares of United Therapeutics by 5.1% during the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock valued at $281,000 after purchasing an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC lifted its holdings in United Therapeutics by 5.4% during the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company's stock worth $276,000 after purchasing an additional 24 shares in the last quarter. Meeder Advisory Services Inc. boosted its stake in United Therapeutics by 4.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company's stock worth $392,000 after purchasing an additional 26 shares during the period. Finally, Independent Advisor Alliance boosted its stake in United Therapeutics by 3.3% in the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company's stock worth $406,000 after purchasing an additional 27 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Stock Down 2.4%

UTHR opened at $515.46 on Friday. The business's fifty day simple moving average is $530.46 and its 200 day simple moving average is $538.70. United Therapeutics Corporation has a 52 week low of $303.08 and a 52 week high of $609.35. The stock has a market cap of $22.11 billion, a PE ratio of 18.44, a P/E/G ratio of 1.79 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same quarter in the previous year, the company posted $6.41 earnings per share. The company's revenue was down 1.9% compared to the same quarter last year. As a group, equities analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Insider Buying and Selling

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total transaction of $4,342,062.00. Following the transaction, the executive vice president directly owned 45,172 shares of the company's stock, valued at approximately $23,631,280.08. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business's stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $517.28, for a total transaction of $4,914,160.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company's stock, valued at approximately $167,827,875.04. The trade was a 2.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 424,075 shares of company stock valued at $227,336,485 in the last 90 days. 8.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have recently commented on UTHR. TD Cowen restated a "buy" rating on shares of United Therapeutics in a research report on Thursday, May 21st. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a report on Thursday, August 6th. Bank of America lowered their target price on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research note on Friday, July 10th. Wells Fargo & Company raised shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Royal Bank Of Canada lowered their price objective on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a research report on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source